Neurocrine Biosciences, Inc. $NBIX Shares Newly Purchased by Privium Fund Management B.V.

Privium Fund Management B.V. purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 26,200 shares of the company’s stock, valued at approximately $3,716,000. Neurocrine Biosciences makes up approximately 0.7% of Privium Fund Management B.V.’s holdings, making the stock its 27th largest position.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $2,310,886,000. Renaissance Technologies LLC lifted its position in shares of Neurocrine Biosciences by 8.0% during the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock worth $318,665,000 after purchasing an additional 180,100 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock valued at $126,367,000 after purchasing an additional 472,408 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at approximately $117,827,000. Finally, Ieq Capital LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at approximately $107,914,000. Institutional investors own 92.59% of the company’s stock.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider David Boyer sold 826 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $157.45, for a total transaction of $130,053.70. Following the completion of the sale, the insider owned 8,722 shares in the company, valued at approximately $1,373,278.90. The trade was a 8.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the transaction, the chief financial officer directly owned 42,808 shares in the company, valued at approximately $6,729,417.60. This trade represents a 5.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 18,137 shares of company stock valued at $2,829,332. Company insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Trading Up 3.0%

Shares of NASDAQ:NBIX traded up $4.87 during trading on Friday, hitting $164.63. 1,507,459 shares of the company’s stock were exchanged, compared to its average volume of 1,232,670. The firm has a market cap of $16.73 billion, a P/E ratio of 24.43, a PEG ratio of 0.64 and a beta of 0.36. The firm has a 50-day moving average price of $147.22 and a two-hundred day moving average price of $148.05. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, beating the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 24.11%. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the business posted $2.04 earnings per share. Neurocrine Biosciences’s revenue was up 41.3% compared to the same quarter last year. As a group, research analysts predict that Neurocrine Biosciences, Inc. will post 7.66 EPS for the current year.

Analysts Set New Price Targets

NBIX has been the subject of a number of research reports. Royal Bank Of Canada raised their price target on shares of Neurocrine Biosciences from $187.00 to $190.00 and gave the company an “outperform” rating in a report on Tuesday. Citigroup upped their price objective on Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. TD Cowen increased their price objective on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wells Fargo & Company lifted their target price on Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Finally, Stifel Nicolaus boosted their target price on Neurocrine Biosciences from $188.00 to $215.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $202.32.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.